Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaxis has reported that the Korean regulatory agency has granted marketing approval for its asthma management product, Aridol.
Subscribe to our email newsletter
Approval by the Korean regulatory agency was based on the Australian approval and was completed efficiently in just six months. The approval process is expected to conclude in the third quarter of 2008.
Pharmaxis will now commence pre-marketing with its Korean distributor BL&H, while seeking reimbursement approval through the national health scheme.
Alan Robertson, CEO of Pharmaxis, said: “This is the first Asian approval of Aridol. The existing broad acceptance of lung function challenge tests presents a firm opportunity for marketing Aridol.”